Senores Pharmaceuticals Acquires Apnar Pharma for INR 91 Cr

The acquisition strengthens Senores Pharmaceuticals’ API manufacturing base, improving backward integration and supporting expansion across regulated global markets.

Senores Pharmaceuticals has announced the acquisition of Apnar Pharma for ₹91 crore, reinforcing its strategy to expand manufacturing capabilities and strengthen its presence in the active pharmaceutical ingredients (API) segment.

The acquisition is aimed at enhancing backward integration and supporting Senores’ growing formulation and API business across regulated markets.

Apnar Pharma brings established API manufacturing infrastructure and technical expertise, which will complement Senores’ existing portfolio.

The integration is expected to improve supply-chain reliability, cost efficiencies, and product development capabilities, particularly for complex and high-value APIs.

Keyur Parikh, Founder and Managing Director, Senores Pharmaceuticals, said, “This acquisition aligns with our long-term vision of building a vertically integrated pharmaceutical platform. Apnar Pharma’s manufacturing strengths will accelerate our ability to scale API production and support our formulation pipeline for regulated markets.”

The acquisition also supports Senores’ expansion strategy in international markets, where regulatory compliance, consistent API supply, and quality assurance are critical.

By strengthening its manufacturing base, the company aims to improve time-to-market and reduce dependency on third-party suppliers.

Industry observers note that consolidation in the API space is gaining momentum as pharmaceutical companies seek greater control over supply chains amid global disruptions.

Senores’ acquisition of Apnar Pharma positions the company to capitalize on this trend while reinforcing India’s role as a global pharmaceutical manufacturing hub.

Senores Pharmaceuticals, headquartered in Ahmedabad, is a formulation- and API-focused pharmaceutical company serving regulated global markets, while Gujarat-based Apnar Pharma is an established API manufacturer with expertise in complex molecules and scalable production infrastructure.

Stay tuned for more such updates on Digital Health News